Vestagen Completes First Clinical Trial
Vestagen Technical Textiles today announced the completion of the first clinical trial involving its Vestex™ nanotechnology-based products. The clinical trial was conducted by the Department of Epidemiology and Infection Control at Virginia Commonwealth University.
Medical research has consistently documented that garments and fabrics used in the healthcare environment are contaminated with high levels of dangerous microbes such as MRSA, which may pose a threat to health care workers, their patients and the community. The 16-week, blinded cross-over clinical trial compared levels of bacterial contamination, known as Colony Forming Unit counts, on Vestex treated scrubs versus standard scrubs. More than 300 cultures were performed on 32 health care workers in a medical respiratory intensive care unit.
The study was led by Gonzalo Bearman, MD, MPH, associate professor of medicine, epidemiology and community medicine at VCU. “The results for this study are encouraging,” said Bearman, “as the Vestex scrubs had significantly fewer MRSA colonies.”
The performance of Vestex is the result of impregnated nano-sized particles that change the surface area of the fabric, increasing surface tension. The proprietary technology creates a barrier to contaminants and fluids such as blood. The repellency of the barrier protection sheds bulk contaminants allowing the imbedded antimicrobial properties of Vestex to control microorganisms on the fabric.